Samuel Hellman to Male
This is a "connection" page, showing publications Samuel Hellman has written about Male.
Connection Strength
0.111
-
Early prostate cancer: hedonic prices model of provider-patient interactions and decisions. Int J Radiat Oncol Biol Phys. 2008 Mar 15; 70(4):1158-68.
Score: 0.016
-
Hormone therapy and radiotherapy for early prostate cancer: a utility-adjusted number needed to treat (NNT) analysis. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):687-94.
Score: 0.013
-
Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. Cancer. 2003 Dec 01; 98(11):2351-61.
Score: 0.012
-
Early prostate cancer: clinical decision-making. Lancet. 2003 Mar 22; 361(9362):1045-53.
Score: 0.012
-
An evidence-based analysis of the management of localized prostate cancer. Cancer J. 2002 Jan-Feb; 8(1):40-6.
Score: 0.011
-
Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 05 04; 9(1):1793.
Score: 0.008
-
Race and the Will Rogers phenomenon in prostate cancer. Cancer J Sci Am. 1998 Jan-Feb; 4(1):27-34.
Score: 0.008
-
Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am. 1996 Jul-Aug; 2(4):225-33.
Score: 0.007
-
Radiation oncology. JAMA. 1996 Jun 19; 275(23):1852-3.
Score: 0.007
-
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
Score: 0.005
-
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
Score: 0.004
-
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83.
Score: 0.003
-
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
Score: 0.003